DEC 0 7 2005



Vertex Pharmaceuticals Incorporated
130 Waverly Street • Cambridge, MA 02139-4242
Tel. 617.444.6100 • Fax 617.444.6483
http://www.vrbx.com

FAX TRANSMISSION

То	USPTO
Examiner	Thomas C. McKenzie, Ph.D.
Fax Number	(571) 273-8300
From	Karen E. Brown
Date	December 7, 2005
Application No.	10/035,823
Attorney Docket No.	VPI/99-01 CON US
	Status Inquiry
Total Pages	011

Message or Comment

If any problems occur with this fax transmittal, please call (617) 444-6168 immediately.

DEC 0 7 2005

Attorney Docket No.: VPI/99-01 CON US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/035,823

Confirmation No.:

1783

Filing Date:

October 23, 2001

Examiner:

Thomas C. McKenzie, Ph.D.

Group Art Unit:

1624

Applicants:

Francesco G. Salituro et al.

For:

INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)

Certificate of Facsimile Transmission Under 37 CFR §1.8

I hereby certify that this correspondence and any documents referred to as attached hereto is/arc being facsimile transmitted to the United States Patent and Trademark Office on December 7, 2005.

Knowne

December 7, 2005

Cambridge, Massachusetts

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith: [X] a Status Inquiry; [] a Petition for Extension of Time; [] a substitute Specification; [] a Declaration; [] a Supplemental Declaration; [] a Power of Attorney; [] an Associate Power of Attorney; [] formal drawings; [] Notice of Appeal; [] Appeal Brief; [] Petition for Revival; to be filed in the above-identified patent application.

Applicants: Francesco G. Salituro et al. Application No. 10/035,823

FEE FOR ADDITIONAL CLAIMS

[X]	A fee for additiona	I claims is	not required.
-----	---------------------	-------------	---------------

[] A fee for additional claims is required.

The additional fee has been calculated as shown below:

	RI AI	AIMS EMAINING TER MENDMENT	HIGHEST NUMBER PREVIOU PAID FOR	SLY	PRESENT EXTRA	RATE		ODITIO ES	NAL
тотл	AL CLA	IMS	-	* =	х	\$ 50		\$	0
INDE ÇLAI	PENDI IMS	ENT	_	** ==	x	\$200	=	\$	0
		ENTATION OF			+	\$360	=	\$	
* **		s than 20, insert s than 3, insert 3			TOTAL			<u>\$</u>	0
	[] A check in the amount of \$ in payment of the filing fee is transmitted herewith.								
	[] Please charge \$ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.						ling		
	[X] The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.								

Applicants: Francesco G. Salituro et al. Application No. 10/035,823

EXTENSION FEE

	ا المعاديد الله الله الله الله الله الله الله الل
[]	The following extension is applicable to the Response filed herewith; [] \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); [] \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); [] \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); [] \$1,590.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); [] \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).
[]	A check in the amount of [] \$120.00; [] \$450.00; [] \$1,020.00; [] \$1,590.00; [] \$2,160.00 in payment of the extension fee is transmitted herewith.
0	Please charge the extension fee in the amount of [] \$120.00; [] \$450.00; [] \$1,020.00; [] \$1,590.00; [] \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
[X]	The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
MISC	ELLANEOUS FEES
[]	Please charge \$ to Deposit Account No. 50-0725 in payment of the for (37 C.F.R. §).

Respectfully submitted,

Karen E. Brown, Reg. No. 43,866
Attorney/Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483

DEC 0 7 2005

Attorney Docket No.: VPJ/99-01 CON US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/035,823

Confirmation No.:

1783

Filing Date:

October 23, 2001

Examiner:

Thomas C. McKenzie, Ph.D.

Group Art Unit:

1624

Applicants:

Francesco G. Salituro et al.

For:

INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)

Certificate of Facsimile Transmission Under 37 CFR §1.8

I hereby certify that this correspondence and any documents referred to as attached hereto is/are being facsimile transmitted to the United States Patent and Trademark Office on December 7, 2005.

December 7, 2005

Cambridge, Massachusetts

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith: [X] a Status Inquiry; [] a Petition for Extension of Time; [] a substitute Specification; [] a Declaration; [] a Supplemental Declaration; [] a Power of Attorney; [] an Associate Power of Attorney; [] formal drawings; [] Notice of Appeal; [] Appeal Brief; [] Petition for Revival; to be filed in the above-identified patent application.

Applicants: Francesco G. Salituro et al. Application No. 10/035,823

FEE FOR ADDITIONAL CLAIMS

- [X] A fee for additional claims is not required.
- [] A fee for additional claims is required.

The additional fee has been calculated as shown below:

	RE:	AIMS MAINING TER IENDMENT	HIGHEST NUMBER PREVIOUS PAID FOR	SLY	PRESE EXTRA		RATE		ODITIO	NAL
TOTA	L CLA	IMS	-	* =		x	\$ 50	=	\$	0
INDEI CLAIN	PENDE MS	NT	-	** =		х	\$200	=	\$	0
		ENTATION O				+	\$360	=	\$	
*		than 20, insert than 3, insert 3			TOTA	L			\$	0
	[]	A check in the amount of \$ in payment of the filing fee is transmitted herewith.								
	[]	Please charge \$ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.								
	[X]	[X] The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.								

Applicants: Francesco G. Salituro et al. Application No. 10/035,823

EXTENSION FEE

[]	The following extension is applicable to the Response filed herewith; [] \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); [] \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); [] \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); [] \$1,590.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); [] \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).
<u> </u>	A check in the amount of [] \$120.00; [] \$450.00; [] \$1,020.00; [] \$1,590.00

- [] \$2,160.00 in payment of the extension fee is transmitted herewith.
- Please charge the extension fee in the amount of [] \$120.00; [] \$450.00; []\$1,020.00; []\$1,590.00; []\$2,160.00 to Deposit Account No. 50-0725. A []duplicate copy of this transmittal letter is transmitted herewith.
- The Director is hereby authorized to charge payment of any additional fees [X] required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

()	Please charge \$for	to Deposit Account No. 50-0725	
----	---------------------	--------------------------------	--

Respectfully submitted,

Karen E. Brown, Reg. No. 43,866 Attorney/Agent for Applicants

Vertex Pharmaceuticals Incorporated

130 Waverly Street Cambridge, Massachusetts 02139

Tel: (617) 444-6168 Fax: (617) 444-6483

DEC 0 7 2005

VPI/99-01 CON US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Francesco G. Salituro et al.

Application No.:

10/035,823

Confirmation No.:

1783

Group Art Unit:

1624

Examiner

Thomas C. McKenzie, Ph.D.

Filed

October 23, 2001

For

INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)

Cambridge, Massachusetts December 7, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATUS INQUIRY

Sir:

Applicants respectfully inquire as to the status of the above-identified application. No communication has been received since a Petition to Revive an Unintentionally Abandoned Application was filed June 2, 2005.

No fee is deemed necessary in conjunction with the filing of this paper. However, if a fee is required, the Director is hereby authorized to charge any fees due to Deposit Account No. 50-0725. A duplicate copy of this paper is enclosed herewith.

Respectfully submitted,

Karen E. Brown, Reg. No. 43,866

Attorney for Applicants

c/o Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, Massachusetts 02139

Tel.: (617) 444-6168 Fax.: (617) 444-6483

DEC 0 7 2005

VPI/99-01 CON US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Francesco G. Salituro et al.

Application No.:

10/035,823

Confirmation No.:

1783

Group Art Unit:

1624

Examiner

Thomas C. McKenzie, Ph.D.

Filed

October 23, 2001

For

INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)

Cambridge, Massachusetts December 7, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

:

STATUS INQUIRY

Sir:

Applicants respectfully inquire as to the status of the above-identified application. No communication has been received since a Petition to Revive an Unintentionally Abandoned Application was filed June 2, 2005.

No fee is deemed necessary in conjunction with the filing of this paper. However, if a fee is required, the Director is hereby authorized to charge any fees due to Deposit Account No. 50-0725. A duplicate copy of this paper is enclosed herewith.

Respectfully submitted,

Karen E. Brown, Reg. No. 43,866

Attorney for Applicants

c/o Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, Massachusetts 02139

Tel.: (617) 444-6168 Fax.: (617) 444-6483